

# Index

- $\alpha$ -amanitin 30–31
- acute myeloid leukemia (AML)
  - 127–128, 244–246
- adenomatous polyposis coli (APC)
  - 29, 209
- adjuvant tamoxifen therapy 266
- ALK, *see* anaplastic lymphoma kinase
- allele fractions 56–57
- AML, *see* acute myeloid leukemia
- anaplastic lymphoma kinase (ALK)
  - 21, 23, 25–26, 154, 163
- androgen receptor (AR) 89–90
- angiogenesis 6, 17, 24, 78, 147,
  - 150, 177–178, 200, 215, 254
- antibodies 20, 44, 81–82, 127,
  - 150, 156, 180
  - monoclonal 123, 163, 179–181
- antigens 126, 180–181
  - tumor-associated 182
- antitumor 150, 180–182
  - effect 106–107
  - immunity 177–178
  - response 177–178
- APC, *see* adenomatous polyposis coli
- apoptosis 17, 19, 25, 31, 193, 219,
  - 242, 244, 246–247, 254
- AR, *see* androgen receptor
- aspirin 208–209
  
- bevacizumab 23, 118, 180,
  - 203–204, 216, 219
- biomarkers 8–9, 18–20, 22, 46,
  - 88–92, 162–163, 250–251
  - companion tumor 89
  - predictive 19–20, 165, 181
- biomarker status 89
- blood cells
  - red 81, 83
  - white 81, 83
- blood vessels 40, 78
- bone marrow 124, 148, 156
- breast cancer 84–85, 89, 117, 127,
  - 148, 150–151, 158, 207,
  - 244–246, 253, 266–267, 271
  - early 22
  - human 109
  - positive 265–266
- breast cancer cells 125, 151
- breast cancer patients 2, 22, 251,
  - 265, 269, 271
- breast cancer stem cells 253
- breast carcinoma 232–233
  
- cabozantinib 211–212
- CAFs, *see* cancer-associated fibroblasts
- cancer 1–8, 16–17, 25, 27–29,
  - 39–40, 45–47, 103–104,
  - 122–123, 126–129, 145–146,
  - 176–180, 227–229, 240–241,
  - 245–249, 254–255
- bladder 240, 250
- colon 208
- metastatic 59

- nonhematologic 210
- orphan 219
- pancreas 246
- squamous cell 46
- stomach 206, 246
- cancer-associated fibroblasts (CAFs) 114, 147–148
- cancer biology 154, 164, 192, 239, 254
- Cancer Cell Line Encyclopedia (CCLE) 163
- cancer cell lines (CCLs) 6, 114–115, 127, 247, 252
- cancer cell survival 177–178
- cancer cells 5, 7, 21, 31–32, 123, 145–146, 148, 150–151, 154, 156–158, 163–165, 234, 246–247, 254
  - human 254
  - patient-derived 163
- cancer development 2, 105, 204, 245, 255
- cancer drugs 3, 128–129
- Cancer Genome Atlas, The (TCGA) 8, 46, 103
- cancer genomes 42–43, 45, 234
- cancer immunotherapy 175–176, 183
- cancer initiation 122, 148
- cancer mouse models 104
- cancer pathology 228
- cancer patients 6, 9, 54, 58–59, 64, 77, 80, 162–163, 165, 168, 227, 233, 235, 253, 255
  - advanced 57
  - advanced ovarian 207
  - castration-resistant prostate 89
  - colorectal 91
  - early-stage colorectal 90
  - hereditary 8
  - high-risk breast 120
  - localized breast 59
  - metastatic 60
  - metastatic castration-resistant prostate 182
  - metastatic colorectal 60
  - non-metastatic colorectal 87
  - ovarian 155
  - pancreatic 211
  - potential 249
  - rectal 87
  - refractory pancreatic 120
- cancer progression 104, 114, 149, 162, 227, 252
- cancer propagating cells (CPCs) 156
- cancer research 6, 42, 163, 180, 253, 265
- cancer resistance 109, 146, 155, 157, 162
- cancer risk 43
- cancer stem cells (CSCs) 150, 253
- cancer therapy 59, 246
  - personalized 158, 163
- cancer tissue 114, 251
- cancer treatment 2–3, 19, 31, 123, 183
- cancer types 46, 104
- cancer vaccines 151, 175, 181
- carboplatin 19, 195, 207
- carcinoma cells 231
- carcinoma patients 128
- CCLE, *see* Cancer Cell Line Encyclopedia
- CCLs, *see* cancer cell lines
- CDKs, *see* cyclin-dependent kinases
- cell-free DNA 58, 63
- cell lung cancer 88
- cells
  - epithelial 82, 107
  - lymphoid 123, 231
  - malignant 114, 145–146, 156
  - mammalian 241
  - mRNA-positive 88
  - myeloid 150
  - nucleated 82–83
  - smooth-muscle 177–178

- cellular immunotherapy 179, 181  
 CGH, *see* comparative genomic hybridization  
 chemotherapy 7, 15, 19, 25, 85, 87–88, 91, 117, 149, 154–155, 157, 183, 190, 194, 220  
   adjuvant 85, 87  
 chorionic villus sampling (CVS) 61–62  
 chronic lymphocytic leukemia (CLL) 241, 244–246, 248, 250, 253  
 circulating tumor cell (CTC) 5–6, 9, 17, 58, 77–80, 82, 84, 86, 88, 90, 92, 129  
 CLL, *see* chronic lymphocytic leukemia  
 colon cancer patients 87  
 colorectal cancer  
   hereditary nonpolyposis 7–8  
   metastatic 59  
 comparative genomic hybridization (CGH) 42–43  
 Cowden syndrome 200, 217–218  
 CPCs, *see* cancer propagating cells  
 CSCs, *see* cancer stem cells  
 CTC, *see* circulating tumor cell  
 CVS, *see* chorionic villus sampling  
 cyclin-dependent kinases (CDKs) 30–31  
 cytoplasm 242–243
- DCs, *see* dendritic cells  
 DDSP, *see* DNA damage secretory program  
 death, cancer-related 15, 40, 146  
 dendritic cells (DCs) 116, 123–124, 128, 150–151, 164, 177–178, 182  
 DFS, *see* disease-free survival  
 diffuse large B-cell lymphoma (DLBCL) 246, 251
- disease-free survival (DFS) 87–88, 91, 179  
 disease progression 60, 91, 120, 146, 149  
 DLBCL, *see* diffuse large B-cell lymphoma  
 DNA damage secretory program (DDSP) 155–156  
 DNA methylation 27–28, 112, 245  
 DNA mismatch repair genes 208  
 donor-derived DNA 57, 63–65  
 drug resistance 2–3, 6–7, 9, 89, 150, 162, 165  
 drugs, noncancer 32
- early breast cancer (EBC) 22  
 early detection 5–6, 250  
 EBC, *see* early breast cancer  
 EGFR, *see* epidermal growth factor receptor  
 EMs, *see* extensive metabolizers  
 endothelial cells 148, 156, 177–178, 230  
 epidermal growth factor receptor (EGFR) 2, 4–6, 9, 21, 23, 89–90, 108, 149, 154, 180, 203–204, 212, 230  
 epigenetics 2, 9, 27, 247  
 extensive metabolizers (EMs) 267, 270
- FA, *see* Fanconi anemia  
 familial adenomatous polyposis 7–8, 200, 208–209  
 familial adenomatous polyposis (FAP) 7–8, 200, 208–209  
 Fanconi anemia (FA) 210  
 FAP, *see* familial adenomatous polyposis  
 fetal-derived DNA 54, 61–62  
 FGF, *see* fibroblast growth factor

- fibroblast growth factor (FGF) 23, 147, 150
- fibroblasts, cancer-associated 114, 147
- gastric carcinoma 228–233
- gefitinib 3, 23–24, 89
- gemcitabine 21, 106, 118, 150
- GEMMs, *see* genetically engineered mouse models
- genes 4, 7–8, 23, 25, 27, 29, 31–32, 44, 57, 59–60, 106, 157, 204, 209–210, 212
- human 123, 241
- tumor suppressor 2, 27, 108, 206, 209, 218, 220, 248
- genetically engineered mouse models (GEMMs) 104–108, 111–112, 117, 125, 129
- genetic alterations 2, 7–8, 10, 17, 23, 25, 27, 29, 31, 39, 45
- genetic background 117, 250–252
- genetic mutations 41, 213–214
- genome 27–28, 45, 62, 104, 107, 234
- fetal 62, 64
- genomic loci 55–57
- Gorlin syndrome 200, 204–205
- graft-versus-host disease (GVHD) 125
- GVHD, *see* graft-versus-host disease
- HBV, *see* hepatitis B virus
- HDAC, *see* histone deacetylases
- heat shock proteins (HSPs) 192–193
- hemangioblastomas 214–216
- hematopoietic cells 124, 126
- hematopoietic stem cells (HSCs) 124–128
- hepatitis, chronic 40, 43
- hepatitis B virus (HBV) 40
- hepatocellular carcinoma 40, 150, 249, 251
- hereditary cancers 7–8, 107, 199
- hereditary cancer syndromes 7–8, 199–200, 202, 204, 206, 208, 210, 212, 214, 216, 218–220
- hereditary non-polyposis colorectal cancer (HNPCC) 208
- HIPEC, *see* hyperthermic intraperitoneal chemotherapy
- Hippel–Lindau disease 200, 214–215
- histone deacetylases (HDAC) 217, 219
- histone modifications 27–28
- HNPCC, *see* hereditary non-polyposis colorectal cancer
- HSCs, *see* hematopoietic stem cells
- HSPs, *see* heat shock proteins
- human cancer patient samples 254
- human cancers 6, 8, 46, 105, 108–109, 121, 127, 239–240, 242, 244–246, 248–255
- human disease 1, 105–107, 111, 113, 240–241
- humanized mouse models 122–123, 125–128, 164
- human tumors 17, 107, 111–112, 116, 121, 123, 127
- hybridization, comparative genomic 42
- hyperthermic intraperitoneal chemotherapy (HIPEC) 7, 189–197
- immune cells 40, 122–123, 149, 151, 176–177, 179, 183

- response 112, 128, 157, 180–182
- system 7, 112, 121–123, 127, 129, 150, 175–176, 179–180, 182–183, 193
- immunotherapeutic approaches 127, 175–176, 179, 181
- inherited medullary thyroid cancer 211–212
  
- leukemia, chronic lymphocytic 241, 244, 246, 248
- Li-Fraumeni syndrome 200, 218–219
- liver cancer 3, 16, 39–47
  - advanced 41
  - human 45
- liver cirrhosis 40–41
- lung cancer 3–4, 8–9, 15–16, 20–22, 26, 28, 30, 32–33, 88, 107–108, 154, 177, 181–183, 245, 247–248
  - non-small-cell 15
- lung cancer mouse models 108
- Lynch syndrome 200, 208–209
  
- malignant peripheral nerve sheath tumor (MPNST) 201
- MAP, *see* mitogen-activated protein
- massively parallel sequencing (MPS) 53, 56
- mast cells 177–178
- maternal plasma 54, 56, 61–62, 65
- MBC, *see* metastatic breast cancer
- MDSCs, *see* myeloid-derived suppressor cell
- medullary thyroid cancer (MTC) 211–212
- melanoma 42, 45, 58, 111, 116, 157, 163, 217–218
- melphalan 195–196
- mesenchymal cells 40, 157
- mesenchymal stem cells (MSCs) 113, 148, 156
- metabolites 266–267
  - active 265–269
- metastasis 2, 77–78, 112, 115–117, 128, 132, 146, 151, 154, 157, 177–178, 240, 247, 249, 254
- metastatic breast cancer (MBC) 22, 58, 84–85, 240
- miRNA, mature 242–243, 249
- mitogen-activated protein (MAP) 23, 25, 60, 201
- molecular
  - analyses 64, 90, 227
  - characterization 77, 79, 89–91
  - markers 2–3, 5–6, 87, 162
  - pathology 227, 229, 231, 233
  - tests 61, 162, 230, 232
- MPNST, *see* malignant peripheral nerve sheath tumor
- MPS, *see* massively parallel sequencing
- MSCs, *see* mesenchymal stem cells
- MTC, *see* medullary thyroid cancer
  - hereditary 212
- mTOR inhibitors 111, 201, 203–204, 213, 215–218
- mutation
  - analyses 231–232
  - enrichment 57
  - rate 45
- myeloid-derived suppressor cell (MDSCs) 150, 177–178, 180
- myeloid-derived suppressor cells 150, 177
  
- N*-demethyl tamoxifen 268
- natural killer (NK) 122, 151, 177–178
- neurofibromatosis 201, 203–204

- next-generation sequencing (NGS)  
4–6, 8–11, 44–45, 165, 231,  
234, 249
- NGS, *see* next-generation  
sequencing
- NK, *see* natural killer
- NOD-SCID gamma (NSG) 116,  
124–125, 164
- noninvasive diagnostics 53–55
- non-small-cell lung cancer  
(NSCLC) 15, 23, 25–26,  
88–89, 91, 107–108, 117–118,  
182
- Noonan syndrome 213–214
- NSCLC, *see* non-small-cell lung  
cancer
- NSG, *see* NOD-SCID gamma
- objective response rate (ORR) 25,  
203
- oncogenes 2, 27, 30–31, 103–104,  
109, 129, 146, 162, 181, 211,  
245, 247
- oncogenic miRNAs 246–247, 254
- ORR, *see* objective response rate
- ovarian cancer 7, 46, 127,  
206–207  
syndrome 200, 205, 207
- pancreatic cancer 106, 111, 210
- pancreatic ductal adenocarcinoma  
(PDA) 105–106, 147
- pathways, carcinogenic 45, 47
- patient-derived xenograft (PDXs)  
104, 112–113, 115, 117,  
119–122, 125, 164
- patient stratification 132, 165
- pazopanib 212, 215–216
- PBMCs, *see* peripheral blood  
mononuclear cells
- PCT, *see* personalized cancer  
therapy
- PDA, *see* pancreatic ductal  
adenocarcinoma
- PDGF, *see* platelet-derived growth  
factor
- PDXs, *see* patient-derived xenograft
- peripheral blood mononuclear  
cells (PBMCs) 125, 127–128,  
181
- peritoneal surfaces 189–191
- peritoneum 190, 195
- personalized cancer therapy (PCT)  
158–159, 161–164, 168
- personalized immune therapy  
175–176, 178, 180, 182
- PFS, *see* progression-free survival
- pheochromocytoma 211, 214
- platelet-derived growth factor  
(PDGF) 147, 215
- prenatal diagnosis 60, 63, 65
- prenatal diagnostics, noninvasive  
60–61
- primary liver cancer 40
- primary tumors 78, 89–90, 115,  
147, 151
- profiles, fit patient mutation 108
- progenitor cells 106, 128, 164
- prognostic markers 228, 250–251
- progression-free survival (PFS)  
25, 85, 88, 207, 212
- prostate cancer 5, 29, 86, 125,  
181, 206–207, 230  
castration-resistant 60  
castration-resistant metastatic  
86  
lethal 252
- prostate cancer screening 5–6
- prostate-specific antigen (PSA)  
86–87
- prostate-specific membrane  
antigen (PSMA) 86–87
- proteins 17, 20, 30, 45, 110, 114,  
123, 181, 192, 210, 214, 229,  
239–240, 243  
heat shock 23, 192

- Proteus syndrome 200, 218  
 PSA, *see* prostate-specific antigen  
 PSMA, *see* prostate-specific membrane antigen
- RASopathies 200, 213  
 RCCs, *see* renal cell carcinoma  
 receptor tyrosine kinase (RTK) 24, 26, 149, 151  
 renal cell cancers 148, 212  
 renal cell carcinoma (RCCs) 214–216  
 response modifiers, biological 179–180  
 reverse-phase protein array (RPPA) 44  
 RISC, *see* RNA-induced silencing complex  
 RNA-induced silencing complex (RISC) 242–243  
 RPPA, *see* reverse-phase protein array  
 RTK, *see* receptor tyrosine kinase
- SASP, *see* senescence-associated secretory phenotype  
 SCLC, *see* small cell lung cancer  
 selumetinib 107–108  
 senescence-associated secretory phenotype (SASP) 155–156  
 sequencing libraries 56–57  
 single polymorphism (SNP) 252–253  
 small cell lung cancer (SCLC) 88, 107, 117, 240, 249, 252  
 SNP, *see* single polymorphism  
 solid tumors 42, 85, 154, 219, 246–247  
 somatic mutations 2, 16, 46, 57–58, 64  
   actionable 59  
 sorafenib 41, 201, 211, 215
- stage I–III colorectal cancer patients 87  
 stem cells  
   embryonic 253  
   mesenchymal 113, 148, 156  
 stromal cells 104, 155, 164, 177
- tamoxifen dose 269  
 tamoxifen efficacy 265–267, 269  
 tamoxifen therapy 269–271  
   personalized 271  
 TAMs, *see* tumor-associated macrophages  
 taxanes 22  
 TCGA, *see* The Cancer Genome Atlas  
 tetracycline 108–109  
 therapeutic resistance 60, 64, 145–146, 148, 150, 156, 158, 164, 166, 234  
 therapeutic response 117, 146–147, 149, 151, 153, 162, 165  
 therapeutic targets 9, 30, 132, 247, 253–254  
 therapies 4–7, 9, 17–18, 25–27, 79–80, 89–91, 104, 111–114, 121–123, 162–165, 200, 210–211, 218–220, 227, 229–230  
   anticancer 154, 214  
   systemic 41, 60, 204  
 TIC, *see* tumor initiating cell  
 tissues 43, 46, 105, 109, 111, 123, 148, 176, 190, 218, 233, 252  
 TKIs, *see* tyrosine kinase inhibitor  
 TNBC, *see* triple negative breast cancers  
 transcription factors 30, 109, 247  
 transcription inhibition 30–31  
 transfer, adoptive 181, 183

- transgenic mouse models 104–105, 107, 109, 111, 246
- transplant recipients 63, 65
- triple negative breast cancers (TNBC) 251
- TSC, *see* tuberous sclerosis complex
- tuberous sclerosis 200
- tuberous sclerosis complex (TSC) 212–213
- tumor-associated macrophages (TAMs) 148, 150
- tumor biology, recapitulate patient 123
- tumor biopsies 59–60, 79
- tumor cells 7, 17, 77–82, 114–115, 118, 123, 176–181, 193, 230–231
  - rare circulating 77
- tumor growth 106, 111, 114, 151, 180
- tumor heterogeneity 17, 60, 112, 146, 234
- tumorigenesis 17, 104, 106, 122, 129, 148, 150, 179, 193, 201, 215, 240, 253–254
- tumorigenicity 244, 246
- tumorigenic process 105, 109, 111, 176
- tumor-infiltrating 157, 177–178, 183
- tumor initiating cell (TIC) 157
- tumor microenvironment 23, 105, 145–146, 148, 150, 156, 158, 164, 166, 175–178
- tumor progression 42, 92, 105, 147, 176–177, 246, 254
- tumor response rate 207
- tumor samples, patient-derived 129
- tumor suppressors 27, 103–105, 129, 240, 244–245, 247
  - role 244–245
- tumor survivals 148, 254
- tumor tissues 229–230
- tumor types 116, 178
- tumor vaccines 181
- tumor vascularization 148
- tumors 16, 39–40, 44–45, 58–60, 104–111, 113–117, 121–123, 127, 148–149, 154–155, 157–158, 164, 177–179, 192, 230
  - patient-derived 104
- tyrosine kinase inhibitor (TKIs) 3, 9, 25, 89, 108, 204, 207, 210, 212, 215
- vascular endothelial growth factor (VEGF) 147, 180, 204, 212, 215
- VEGF, *see* vascular endothelial growth factor
- vestibular schwannoma 203–204
- warfarin 272
- WGS, *see* whole genome sequencing
- whole genome sequencing (WGS) 4, 9, 56, 62–63, 234
- xenografts, patient-derived tumor 113
- xenopatients 118, 120



*“Likely as the recent Cancer Moonshot Initiative highlights, this book well describes the importance of genetics/genomics-based personalized therapies to improve cancer treatments. This field is growing rapidly, and it is certain that many scientists should obtain professional knowledge of ‘cancer precision medicine’ to cure more cancer patients.”*

**Prof. Yusuke Nakamura**  
University of Chicago, USA

*“At a time when an explosive increase in data has combined with rapidly evolving treatment paradigms, it has become particularly challenging for modern clinicians and medical researchers alike to put these advances in knowledge and practice into a proper context. It is in light of this predicament that this new volume edited by Dr. Il-Jin Kim provides a much-needed organization and harmonic understanding to the cacophony of information regarding the elusive realm of precision medicine. Covering an exhaustive array of topics ranging from the basic science of tumor modeling to the biology of tumor microenvironments to the horizon of cancer immunotherapy and advances for specific cancer types, this clearly written and very readable compilation provides a solid foundation for comprehending the rapidly advancing dawn of a truly new, personalized, precision approach to the treatment and, hopefully, the cure of cancer.”*

**Prof. Michael J. Mann**  
University of California, San Francisco

This book covers almost all fields of cancer genetics and genomics for personalized medicine. Targeted therapy, or precision medicine, or personalized medicine is becoming a standard treatment for many diseases, including cancer. However, how much do we know about the personalized medicine approach? This lucid book helps undergraduate and graduate students, professional researchers, and clinicians to better understand the key concept of personalized medicine.

The most up-to-date topics on personalized medicine in this book cover the recent trends in and updates on lung, gastric, liver, breast, and other types of cancers. Circulating tumor cell, cell-free circulating DNA, and microRNAs are discussed as new diagnostic and prognostic markers for cancer. The avatar mouse model is also discussed for maximizing treatment efficacy and prognosis prediction, and so is microenvironment as a drug resistance mechanism. With classical and new pathological approaches, the book provides a systemic overview of personalized immunotherapies and hyperthermic intraperitoneal chemotherapy, followed by new emerging fields of hereditary cancer, thereby equipping readers to eventually contribute in developing more advanced tools and therapies for curing cancer.



**Il-Jin Kim** is principal investigator and director of Applied Genomics in the UCSF Thoracic Oncology Program. His work focuses on the identification of novel therapeutic targets and diagnostic markers for various types of human cancers. Dr. Kim investigates human cancers using state-of-the-art technologies, including next-generation sequencing (NGS) and system genetic tools that he developed with his team. He has developed several innovative microarrays and pioneered new methods of high-throughput mutation screening, for which he holds numerous patents. He has published more than 70 papers, including in *Science* and *Nature Communications*. He has also received three awards from the American Association for Cancer Research for developing innovative genetic and diagnostic assays. Dr. Kim graduated from the College of Veterinary Medicine, Seoul National University, with a BS and DVM (magna cum laude), and a PhD in tumor biology. In 2010, he joined the UCSF faculty in the Department of Surgery.

